Form 4: Kura Oncology CEO Buys 50,000 Shares

Kura Oncology's President and CEO, Troy Edward Wilson, acquired 50,000 shares of common stock at a weighted average price of $8.2029.

Summary

• Troy Edward Wilson, President & CEO and Director of Kura Oncology, Inc. (KURA), acquired 50,000 shares of common stock.
• The transaction occurred on September 8, 2025, at a weighted average purchase price of $8.2029 per share.
• This purchase was executed in multiple trades at prices ranging from $8.135 to $8.24.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.
• Following this transaction, Mr. Wilson directly owns 100,968 shares of common stock.
• Additionally, Mr. Wilson indirectly owns 279,194 shares through the One Fish Two Fish Revocable Trust and 300,000 shares through the Lorax Charitable Remainder Unitrust.

Sentiment

Score: 8

Explanation: The acquisition of a significant number of shares by the President and CEO indicates strong insider confidence in the company's future performance and valuation.

Positives

• The President and CEO, Troy Edward Wilson, increased his direct ownership in Kura Oncology by acquiring 50,000 shares, signaling confidence in the company's future prospects.
• The purchase was made at a weighted average price of $8.2029 per share, representing a significant personal investment.

Negatives

• No negative information is typically disclosed in a Form 4 filing.

Risks

• No specific risks are detailed in this Form 4 filing, which primarily reports an insider transaction.

Future Outlook

This filing does not contain explicit forward-looking statements or guidance. However, an insider purchase can implicitly signal management's positive outlook on the company's future performance.

Management Comments

• No direct quotes or paraphrased statements from management are provided in this Form 4 filing. The transaction itself serves as a statement of confidence.

Industry Context

Insider buying, particularly by a CEO, is often interpreted by the market as a strong signal of confidence in the company's valuation and future prospects. This action by Kura Oncology's CEO suggests he believes the stock is undervalued or poised for growth, which can be a positive indicator for investors in the biotechnology sector.

Comparison to Industry Standards

• While specific comparable companies or projects are not mentioned in this Form 4, insider buying by a CEO is generally viewed as a positive signal across all industries.
• For example, a similar purchase by the CEO of a peer biotech company like Mirati Therapeutics or Blueprint Medicines would likely be interpreted with similar positive sentiment, indicating management's belief in their respective pipelines or market position.
• The size of the purchase (50,000 shares) relative to the CEO's existing holdings and compensation can also be benchmarked against similar transactions by executives in the biotech space.

Corporate Governance

Related Party Transactions

• Troy Edward Wilson's indirect beneficial ownership through the One Fish Two Fish Revocable Trust and the Lorax Charitable Remainder Unitrust represents related party holdings.

Stakeholder Impact

• Shareholders: May view the CEO's purchase as a positive signal, potentially increasing investor confidence and demand for the stock.
• Employees: Could interpret the CEO's investment as a sign of stability and belief in the company's long-term vision.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing.

Key Dates

Keywords

Kura Oncology, KURA, Troy Edward Wilson, insider buying, CEO stock purchase, Form 4, 10b5-1 plan, common stock